Overview
This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.
Description
PRIMARY OBJECTIVES:
I. Assess the pharmacokinetics of metatine and nicotine electronic (e)-cigarettes.
II. Assess the abuse liability and appeal of commercial e-cigarettes containing metatine versus nicotine.
III. Determine the impact of metatine on e-cigarette puffing behavior (topography).
OUTLINE: Participants attend 3 sessions where they will be randomized to 1 of 3 types of e-cigarette. Participants will use the e-cigarette ad-libitum for 30 minutes and answer survey questions about their perceptions of the e-cigarette. Participants must also undergo 4 blood draws during the vaping session.
Eligibility
Inclusion Criteria:
- Aged 21-34 years
- Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
- Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
- Read and speak English
Exclusion Criteria:
- Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months)
- Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
- History of cardiac event or distress within the past 3 months
- Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
- Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
- Have hemophilia or another type of bleeding disorder
- Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability